FROGG high-risk prostate cancer workshop: Patterns of practice and literature review. Part II post-radical prostatectomy

Journal of Medical Imaging and Radiation Oncology

Volumn 58, Issue 3, 2014, Pages 392-400

  Lehman, Margot ^a   Sidhom, Mark ^e   Kneebone, Andrew B ^d   Hayden, Amy J ^c   Martin, Jarad M ^f   Christie, David ^b   Skala, Marketa ^g   Tai, Keen Hun ^h  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b Premion   (Australia)

^c Westmead Cancer Care Centre   (Australia)

^d SYDNEY CANCER CENTRE   (Australia)

^e Liverpool and Macarthur Cancer Therapy Centres   (Australia)

^f CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^g ROYAL HOBART HOSPITAL   (Australia)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

adjuvant radiation therapy androgen deprivation therapy; pattern of practice survey; prostate cancer; radical prostatectomy; salvage radiation therapy; whole pelvic radiation therapy

Indexed keywords

BICALUTAMIDE; GONADORELIN; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN;

ANDROGEN DEPRIVATION THERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; EVENT FREE SURVIVAL; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS FREE SURVIVAL; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PELVIS LYMPH NODE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SALVAGE PROSTATE BED RADIOTHERAPY; SALVAGE RADIOTHERAPY; SALVAGE THERAPY; SEMINAL VESICLE; SYSTEMATIC REVIEW (TOPIC); TIME TO TREATMENT; TREATMENT FAILURE; WHOLE PELVIC RADIATION THERAPY; WORKSHOP; ADJUVANT CHEMORADIOTHERAPY; AUSTRIA; CLINICAL PRACTICE; EDUCATION; MALE; NEW ZEALAND; PROSTATIC NEOPLASMS; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ANDROGEN ANTAGONISTS; AUSTRIA; CHEMORADIOTHERAPY, ADJUVANT; EDUCATION; HUMANS; MALE; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SALVAGE THERAPY;

EID: 84901827409     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/1754-9485.12139     Document Type: Review

References (49)

1. European association of urology guidelines for prostate cancer. 2013 Update. [Cited 2 Feb 2013.] Available from URL: http://www.uroweb.org/gls/pdf/ 08%20Prostate%20Cancer-LR%20March%2013th%202012.pdf
2. Carver BS, Bianco FJ, Scardino PT, et al. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006; 176: 564-568. (Pubitemid 43927886)
3. Petrovich Z, Lieskovsky G, Stein J, et al. Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer. BJU Int 2002; 89: 604-611. (Pubitemid 34948309)
4. Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol 2004; 172: 910-914. (Pubitemid 39096421)
5. Nguyen CT, Reuther AM, Stephenson AJ, et al. The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival. J Urol 2009; 181: 75-80.
6. Thompson I, Tangen C, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomised clinical trial. J Urol 2009; 181: 956-962.
7. Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380: 2018-2027.
8. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-2930.
9. King C,. Adjuvant versus salvage radiotherapy for high-risk prostate cancer patients. Semin Radiat Oncol 2013; 23: 215-221.
10. Thompson IM, Valicenti R, Albertsen PC, et al. Adjuvant and salvage radiotherapy after prostatectomy: ASTRO/AUA guideline 2013. [Cited Mar 2013.] Available from URL: https://www.auanet.org/education/guidelines/radiation-after- prostatectomy.cfm
11. Bowers Hayes S, Pollack A,. Parameters for treatment decisions for salvage radiation therapy. J Clin Oncol 2005; 23: 8204-8211. (Pubitemid 46211556)
12. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy v observation after radical prostatectomy. JAMA 2008; 299: 2760-2769. (Pubitemid 351846851)
13. Stephenson A, Scardino P, Kattan M, et al. Predicting the outcomes of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035-2041. (Pubitemid 46972788)
14. Goenka A, Magsanoc J, Pei X, et al. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys 2012; 84: 112-118.
15. Sidhom MA, Kneebone AB, Lehman M, et al. Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand radiation oncology genito-urinary group. Radiother Oncol 2008; 88: 10-19.
16. Radiation therapy and androgen deprivation therapy in treating patients who have undergone surgery for prostate cancer (RADICALS). [Cited 15 Mar 2013.] Available from URL: http://clinicaltrials.gov/show/NCT00541047
17. Radiotherapy-adjuvant versus early salvage (RAVES). [Cited 15 Mar 2013.] Available from URL: http://clinicaltrials.gov/ct2/show/NCT00860652
18. Triptorelin and radiation therapy in treating patients who have undergone surgery for intermediate-risk stage III or stage IV prostate cancer (GETUG-17). [Cited 15 Mar 2013.] Available from URL: http://clinicaltrials.gov/show/ NCT00667069
19. Viani G, Stefano E, Afonso S,. Higher than conventional radiation doses in localised prostate cancer treatment: a meta-analysis of randomised, controlled trials. Int J Radiat Oncol Biol Phys 2009; 74: 1405-1418.
20. Bernard J, Buskirk S, Heckman M, et al. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys 2010; 76: 735-740.
21. King C, Spiotto M,. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 2008; 71: 23-27.
22. Cozzarini C, Montorsi F, Fiorino C, et al. Need for high radiation dose (> or =70 Gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients. Int J Radiat Oncol Biol Phys 2009; 75: 966-974.
23. King CR,. The timing of salvage radiotherapy following radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 2012; 84: 104-111.
24. Ohri N, Dicker AP, Trabulsi EJ, Showater TN,. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer 2012; 48: 837-844.
25. Spiotti M, Hancock S, King C,. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patient. Int J Radiat Oncol Biol Phys 2007; 69: 54-61. (Pubitemid 47247505)
26. A Phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy in prostate cancer patients with a rising PSA after radical prostatectomy. RTOG 0534. [Cited 22 Mar 2013.] Available from URL: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study= 0534
27. Van Baelen A, Mottet N, Spahn M, et al. Sense and nonsense of an extended pelvic lymph node dissection in prostate cancer. Adv Urol 2012; 2012: 983058. doi: 10.1144/2012/983058.
28. Boorjian S, Thompson R, Siddiqui S, et al. Longterm outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007; 178: 864-871. (Pubitemid 47211081)
29. Bader P, Burkhard F, Markwalder R, et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003; 169: 849-852.
30. Winter A, Uphoff J, Henke R, et al. Complete PSA remission without adjuvant therapy after secondary lymph node surgery in selected patients with biochemical relapse after radical prostatectomy and pelvic lymph node dissection. Adv Urol 2012; 2012: 609612. doi: 10.1155/2012/609612.
31. Schumacher M, Burkhard F, Thalmann G, et al. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008; 54: 344-352.
32. Briganti A, Karnes J, Da Pozzo L, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009; 55: 261-270.
33. Da Pozzo LF, Cozzarini C, Briganti A, et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 2009; 55: 1003-1006.
34. Briganti A, Karnes RJ, Da Pozzo LF, et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4pN+ prostate cancer: results of a matched analysis. Eur Urol 2011; 59: 832-840.
35. Kaplan JR, Kowalczyk KJ, Borza T, et al. Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy. BJU Int 2013; 111: 1208-1214.
36. Deville C, Vapiwala N, Hwang WT, et al. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys 2012; 82: 1389-1396.
37. Bastide C, Rossi D, Lechevallier E, et al. Seminal vesicle invasion: what is the best adjuvant treatment after radical prostatectomy? BJU Int 2012; 109: 525-530.
38. Ost P, Fonteyne V, Villeirs G, et al. Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. Eur Urol 2009; 56: 669-677.
39. Ost P, De Troyer B, Fonteyne V, et al. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1316-1322.
40. Pai H, Eldridge B, Bishop D, et al. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy? Can J Urol 2009; 16: 4541-4552.
41. Ost P, Cozzarini C, Meerleer G, et al. High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. Int J Radiat Oncol Biol Phys 2012; 83: 960-965.
42. King C, Presti J, Gill H, et al. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? Int J Radiat Oncol Biol Phys 2004; 59: 341-347. (Pubitemid 38622584)
43. Shipley W, Hunt D, Lukka H, et al. Initial report of RTOG 9601: a phase III trial in prostate cancer: anti-androgen therapy with bicalutamide during and after radiation therapy improves freedom from progression and reduces the incidence of metastatic disease in patients following radical prostatectomy with pT2-3, N0 disease and elevated PSA levels (abstract). Int J Radiat Biol Phys 2010; s27.
44. Radiation therapy with or without goserelin in treating patients who have undergone surgery for recurrent or regractory prostate cancer. FRE-FNCLCC-GETUG-16/0504, EU-20668, EUDRACT-2005-005165, NCT00423475. [Cited 22 Mar 2013.] Available from URL: http://www.cancer.gov/clinicaltrials/search/view? cdrid=523446&version=HealthProfessional
45. Kumar S, Shelley M, Harrison C, Coles B, Wilt T, Mason M,. Neoadjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database of Syst Rev 2006; (4): CD006019. doi: 10.1002/14651858. CD006019.pub2.
46. Messing EM, Manola J, Yao J,. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-479. (Pubitemid 43779173)
47. Dorff T, Flaig T, Tangen C, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011; 29: 2040-2045.
48. Rozet F, Culine S, Soulié M, et al. Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of recurrence. Protocol. [Cited 22 Mar 2013.] Available from URL: http://www.urofrance.org/fileadmin/medias/recherche/protocoles/getug-20/ protocole-getug-20-2011-2011-16-v5.pdf
49. Wiegel T, Bottke D, Bartkowiak D, et al. Phase III results of adjuvant radiotherapy versus wait-and-see in patients with pT3 prostate cancer following radical prostatectomy (ARO 96-02/AUO AP09/95): ten years follow-up. J Clin Oncol 2013; 31 (6-suppl (February 20 Suppl.)): 4.